Status:
WITHDRAWN
Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy
Lead Sponsor:
University of California, Davis
Collaborating Sponsors:
Forest Laboratories
Conditions:
Epilepsy
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
People with epilepsy often experience problems with their memories and other thinking skills that get worse over time. The investigators hope to learn more about whether a drug called memantine can he...
Detailed Description
This is a double-blind, placebo-controlled trial of the effects of memantine in adult epilepsy patients. Patients will be assessed for neurocognitive outcomes, seizure frequency and side effects. Afte...
Eligibility Criteria
Inclusion
- Adult patients with temporal lobe epilepsy, aged 18-65
- Seizure frequency of less than three per month
- Stabilized treatment for epilepsy, including AEDs and vagus nerve stimulation
- Intelligence Quotient of \>70
- Native English speaker (most of the neuropsychological/cognitive tests have yet to be translated and/or validated in non-English speaking populations. Thus, at this point we are limited to testing English speakers, only.)
- Able to count seizures accurately and maintain a seizure diary
- Recent AED levels performed within the last month within therapeutic range
Exclusion
- Progressive neurologic disease
- Severe medical illness, including renal insufficiency
- Severe depression, bipolar disease or psychosis
- Pregnant or lactating women.
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00986115
Start Date
July 1 2010
End Date
April 1 2012
Last Update
May 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Davis
Sacramento, California, United States, 95817